TP53 and prostate adenocarcinoma: Comparing our pooled results with data from the SU2C‐PCF dataset, the prevalence of PTEN loss in NEPC was similar to that in advanced prostate adenocarcinoma, while RB1 and TP53 were more frequently altered in NEPC.30